Patents Issued in February 1, 2022
-
Patent number: 11234991Abstract: Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liquid droplets from the HPLC eluent; drying the liquid droplets to obtain residue particles of the sterol; contacting the residue particles of the sterol with an ion stream which applies a size-dependent electrical charge to each of the residue particles to generate an electrical signal and measuring the electrical signal to determine the purity of the sterol in the sample. The sterol can be OXY133 or OXY133 monohydrate.Type: GrantFiled: February 24, 2020Date of Patent: February 1, 2022Assignee: Warsaw Orthopedic, Inc.Inventors: Roger E. Harrington, Jerbrena C. Jacobs
-
Patent number: 11234992Abstract: The disclosure provides for therapies and methods to treat atherosclerosis and/or hyperlipidemia, and complications resulting therefrom, with compositions that comprise therapeutically effective amounts of one or more human milk oligosaccharides.Type: GrantFiled: February 28, 2019Date of Patent: February 1, 2022Assignee: The Regents of the University of CaliforniaInventors: Philip Gordts, Ariane Pessentheiner, Lars Bode
-
Patent number: 11234993Abstract: The present invention provides an alcohol extract of Ajuga taiwanensis Nakai ex Murata exhibits significant effects on inhibiting the senescence in human WI-38 lung fibroblasts and human dermal fibroblasts. Moreover, the alcohol extract of A. taiwanensis is able to suppress the expression of the cofilin-1, a protein involved in actin dynamics and cell morphology and found to be increased in senescent cells. Suppression effect of cell senescence by this herb extract is more efficient in mild concentration without over-inhibition of cell viability and growth.Type: GrantFiled: May 26, 2020Date of Patent: February 1, 2022Assignee: NATIONAL YANG-MING UNIVERSITYInventors: Yi-Jang Lee, Yun-Lian Lin, Chung-Sheng Huang, Cheng-Han Tsai, Chun-Yuan Chang, Bing-Ze Lin, Yuan-Heng Tu, Wei-Hsiang Hsu, Pin-Ho Lo
-
Patent number: 11234994Abstract: The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.Type: GrantFiled: April 13, 2017Date of Patent: February 1, 2022Assignee: Benitec Biopharma LimitedInventors: David Suhy, Michael Graham, Capucine Trollet, Alberto Malerba, John George Dickson
-
Patent number: 11234995Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of ?-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an ?-synudein gene, has activity for inhibiting expression of the ?-synudein gene, and is complementary to the ?-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.Type: GrantFiled: January 5, 2017Date of Patent: February 1, 2022Assignees: OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITIONInventors: Masayuki Nakamori, Hideki Mochizuki, Satoshi Obika, Takanori Yokota, Tetuya Nagata, Yuya Kasahara
-
Patent number: 11234996Abstract: Described herein are methods for treating fibrosis, e.g., kidney fibrosis, using agents that target Secreted Modular Calcium-binding protein 2 (SMOC2).Type: GrantFiled: February 21, 2017Date of Patent: February 1, 2022Assignee: The Brigham and Women's Hospital, Inc.Inventors: Vishal S. Vaidya, Casimiro Gerarduzzi
-
Patent number: 11234997Abstract: The invention relates to topical formulations comprising: a galactooligosaccharide; 0.01% to 10% w/w xylitol; and a pharmaceutically or cosmetically acceptable carrier. The invention also relates to use of the formulations, and methods for their preparation.Type: GrantFiled: June 27, 2018Date of Patent: February 1, 2022Inventors: Andrea Zanardi, Alessandra Cercaci, Ivan Montaldo
-
Patent number: 11234998Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.Type: GrantFiled: March 17, 2020Date of Patent: February 1, 2022Assignee: Tricol Biomedical, Inc.Inventors: Simon McCarthy, Barbara McGrath, Sam Kuhn, Jess Kimball, Michael Stolten, Amanda Bennett
-
Patent number: 11234999Abstract: It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.Type: GrantFiled: February 3, 2020Date of Patent: February 1, 2022Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN REDInventors: Vicente Maria Lorenzo-Zúñiga García, Ramon Bartolí Solé, Jaume Boix Valverde
-
Patent number: 11235000Abstract: The invention provides CaO2 nanoparticles having a pH-responsive coating for use in a method of adjuvant therapy of hypoxic tumour cells or tissues. The nanoparticles find particular use in enhancing cancer therapies that depend on oxygen to exert their effect, such as photodynamic therapy (PDT), sonodynamic therapy (SDT), and radiotherapy. The invention also provides pharmaceutical compositions containing the coated CaO2 nanoparticles, together with at least one photosensitiser, sonosensitiser, or radiosensitiser and, optionally, at least one pharmaceutical carrier or excipient.Type: GrantFiled: May 4, 2018Date of Patent: February 1, 2022Assignee: UNIVERSITY OF ULSTERInventors: Anthony Mchale, John Callan, Yingjie Sheng
-
Patent number: 11235001Abstract: Provided are a RUNX inhibitor which binds to a RUNX-binding sequence on DNA and thus inhibits the binding of a RUNX family member to the sequence; an antitumor agent comprising the RUNX inhibitor; and an antiallergic agent comprising the RUNX inhibitor.Type: GrantFiled: July 21, 2017Date of Patent: February 1, 2022Assignee: KYOTO UNIVERSITYInventors: Hiroshi Sugiyama, Yasuhiko Kamikubo
-
Patent number: 11235002Abstract: Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.Type: GrantFiled: May 14, 2019Date of Patent: February 1, 2022Assignee: Galleon Labs LLCInventors: Gary S. Hahn, Siva Gudi
-
Patent number: 11235003Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.Type: GrantFiled: December 18, 2009Date of Patent: February 1, 2022Assignee: APOSCIENCE AGInventor: Hendrik Jan Ankersmit
-
Patent number: 11235004Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.Type: GrantFiled: June 29, 2018Date of Patent: February 1, 2022Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
-
Patent number: 11235005Abstract: This invention relates to a method for repairing and reconstructing a damaged or non-functional muscle, in particular to a method and a tool kit using in vitro primed motor endplate-expressing muscle progenitor cells (MPCs) to promote innervation of the damaged or non-functional muscle using an agent without any genetic manipulation. This method is particularly useful for repairing or reconstructing damaged or non-functional head and neck muscles, and urinary detrusor bladder muscle.Type: GrantFiled: April 27, 2018Date of Patent: February 1, 2022Assignee: Purdue Research FoundationInventor: Stacey L. Halum
-
Patent number: 11235006Abstract: An inhibiting or alleviating agent for amyloid beta (A?)-induced damage in hippocampus including an extract from inflamed tissues inoculated with vaccinia virus. Also relates to the use of the extract from inflamed tissues inoculated with vaccinia virus in the preparation of an agent for inhibiting or alleviating A?-induced damage in hippocampus.Type: GrantFiled: March 6, 2017Date of Patent: February 1, 2022Assignees: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventor: Jun Liu
-
Patent number: 11235007Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.Type: GrantFiled: October 18, 2018Date of Patent: February 1, 2022Assignee: MiMedx Group, Inc.Inventors: Brenda S. Morse, Somaly Sith, Randall Spencer, Steven Ray, John Daniel, Robert Tofe
-
Patent number: 11235008Abstract: The present application relates to nutritional compositions comprising lactic acid-producing bacteria.Type: GrantFiled: March 29, 2012Date of Patent: February 1, 2022Assignee: Ganeden Biotech, Inc.Inventors: Sean Farmer, David Keller, Andrew R. Lefkowitz
-
Patent number: 11235009Abstract: The present invention provides a method of improving the phenomenon of the glomerular sclerosis and mononuclear leukocyte infiltration around renal tissues, and increasing the renal function by administering the probiotic bacterium of a Parabacteroides goldsteinii to a subject in need to inhibit the occurrence of chronic kidney disease. The Parabacteroides goldsteinii can also effectively modulate the gene expression level of MCP-1, IL-1?, COL3A, COL6A1, ACAA2, PPAR-?, CPT1, and PGC-1? in kidney tissues to reduce kidney inflammation and renal fibrosis and enhance the mitochondria activity of kidney cells. Therefore, the Parabacteroides goldsteinii of the present invention can be utilized in pharmaceutical compositions for inhibiting or treating chronic kidney diseases.Type: GrantFiled: September 3, 2019Date of Patent: February 1, 2022Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITEDInventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai
-
Patent number: 11235010Abstract: A composition is described that includes at least one lactic acid bacteria, preferably Lactobacillus johnsonii LA1 NCC 533 (deposit number CNCM I-1225) in an acceptable carrier. Also described, is use of the composition in the treatment and/or prevention of a dermatological disease, preferably atopic dermatitis.Type: GrantFiled: October 7, 2016Date of Patent: February 1, 2022Assignee: GALDERMA RESEARCH & DEVELOPMENTInventor: Carine Rosignoli
-
Patent number: 11235011Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.Type: GrantFiled: November 12, 2019Date of Patent: February 1, 2022Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
-
Patent number: 11235012Abstract: Formulations comprising a combination of red propolis and red algae, e.g., L. calcareum, as active ingredients, and methods of treatment using the same are provided herein. In various embodiments, the formulation may be in the form of, e.g., an aqueous solution or suspension, an ingestible solid or liquid form, or a topical preparation, and may be used to treat a variety of diseases and conditions responsive to the combination.Type: GrantFiled: June 30, 2020Date of Patent: February 1, 2022Inventor: Walter A. Bretz
-
Patent number: 11235013Abstract: The present disclosure relates to a dissolvable thin oral tape, film or strip or segment thereof composition or device, including a film former, at least one cannabinoid, menthol, caffeine and vitamins, where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.Type: GrantFiled: March 3, 2020Date of Patent: February 1, 2022Inventors: Babak Ghalili, Emma Ghalili
-
Patent number: 11235014Abstract: Provided herein are custom therapeutic compositions combining select Chinese herbs and strains of Cannabis, methods of making the compositions, and methods of using the composition for treatment of headache pain.Type: GrantFiled: April 10, 2020Date of Patent: February 1, 2022Inventor: Artashes Mirzatuny
-
Patent number: 11235015Abstract: An antiviral traditional Chinese medicine composition, a preparation method therefor and a pharmaceutical application thereof. The composition uses Herba Taraxaci, Radix Stemonae, Pseudobulbus Cremastrae Seu Pleiones, Radix Puerariae, Rhizoma Atractylodis Macrocephalae, and Radix Cynanchi Atrati as main active pharmaceutical ingredients, may also optionally and additionally use Cortex Lycii Radicis and Cortex Mori as active pharmaceutical ingredients, and is prepared into a pharmaceutically acceptable dosage form according to needs. The medicine composition is effective against influenza A virus, H1N1, H7N7 and H9N2 viruses, Zika virus, dengue virus I, dengue virus II, and Chikungunya virus.Type: GrantFiled: May 15, 2018Date of Patent: February 1, 2022Inventor: Hongzhang Jia
-
Patent number: 11235016Abstract: The use of Salvia haenkei extract is described as a re-epithelizing and cicatrizing agent in the treatment of tissue lesions. Pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients for use in the treatment of tissue lesions are also disclosed.Type: GrantFiled: December 14, 2018Date of Patent: February 1, 2022Assignee: Altergon SAInventors: Andrea Alimonti, Andrea Maria Giori, Monica Montopoli, Jessica Cadau
-
Patent number: 11235017Abstract: The use of Salvia haenkei extract as an active agent in the treatment of dermatological diseases is described. Also described are pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of dermatological diseases.Type: GrantFiled: December 14, 2018Date of Patent: February 1, 2022Assignee: Altergon SAInventors: Andrea Alimonti, Andrea Maria Giori, Monica Montopoli, Jessica Cadau
-
Patent number: 11235018Abstract: The present invention provides a pharmaceutical composition for preventing or treating cancer, a food composition for enhancing immune functions, and a pharmaceutical composition for preventing or treating cachexia. The composition of the present invention provides effects of further inhibiting the growth of tumors, increasing immunological activity, and suppressing cachexia caused by tumors. In addition, the composition of the present invention can obtain a synergistic effect when co-administered with an existing anticancer drug.Type: GrantFiled: January 16, 2019Date of Patent: February 1, 2022Assignee: OKCHUNDANG CO., LTD.Inventors: Sae Kwang Ku, Seong Min Ku, Tae Hun Ku, Chui Jong Jung, Gyung Yun Beik, Jin Gi Shin, Sang Soo Lee, Jeong Gyun Seo, Chil Surk Yoon, Xian Li
-
Patent number: 11235019Abstract: Some embodiments comprise dietary supplements for treating or preventing traveler's diarrhea comprising: (a) about 1000 mg green tea extract comprising at least 90% (w/w) catechins; (b) about 4 g partially hydrolyzed guar gum (PHGG); (c) about 100 mg L-theanine; and (d) about 5 g non-sugar sweetener, wherein the sweetener does not contain a polyol. Some embodiments comprise dietary supplement for treating or preventing traveler's diarrhea comprising: (a) from about 250 mg to about 1,500 mg green tea extract comprising at least 90% (w/w) catechins; (b) from about 1 g to about 8 g partially hydrolyzed guar gum (PHGG); and (c) from about 15 mg to about 250 mg L-theanine.Type: GrantFiled: April 12, 2017Date of Patent: February 1, 2022Assignee: ARTESA LLCInventor: William E. Driessen
-
Patent number: 11235020Abstract: Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.Type: GrantFiled: March 12, 2014Date of Patent: February 1, 2022Inventors: Abraham Palmer, Margaret Distler, Katherine M. J. McMurray
-
Patent number: 11235021Abstract: A solid antimicrobial hydrogel comprising a first amphiphilic component. The first amphiphilic component, in its chemically cross-linked state, being a lyotropic liquid crystal and having an ordered nanostructure of hydrophobic and hydrophilic domains, the composition further comprising an antimicrobial agent being covalently attached to at least one of the hydrophilic or hydrophobic domains.Type: GrantFiled: October 1, 2018Date of Patent: February 1, 2022Assignee: AMFERIA ABInventors: Anand Kumar Rajasekharan, Saba Atefykta, Martin Andersson
-
Patent number: 11235022Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.Type: GrantFiled: May 29, 2020Date of Patent: February 1, 2022Assignee: Cedars-Sinai Medical CenterInventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
-
Patent number: 11235023Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.Type: GrantFiled: May 31, 2017Date of Patent: February 1, 2022Assignee: POLYPHOR AGInventors: Christian Ludin, Manfred Keller
-
Patent number: 11235024Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.Type: GrantFiled: May 31, 2017Date of Patent: February 1, 2022Assignee: POLYPHOR AGInventors: Christian Ludin, Manfred Keller, Piet Bruijnzeel, Johann Zimmermann, Philip Barth, Eric Chevalier
-
Patent number: 11235025Abstract: The present invention relates to an Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and to a pharmaceutical composition containing the same as an active ingredient. The Nkx3.2 fragment of the present invention has a function to activate NF-?B at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.Type: GrantFiled: November 9, 2017Date of Patent: February 1, 2022Assignee: ICM CO., LTD.Inventor: Dae-Won Kim
-
Patent number: 11235026Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.Type: GrantFiled: July 12, 2018Date of Patent: February 1, 2022Assignee: Sangamo Therapeutics, Inc.Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
-
Patent number: 11235027Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.Type: GrantFiled: May 16, 2018Date of Patent: February 1, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Peter Luke Santa Maria, Yunzhi Peter Yang, Sungwoo Kim, Chloe Domville-Lewis
-
Patent number: 11235028Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.Type: GrantFiled: July 31, 2019Date of Patent: February 1, 2022Assignee: The Cleveland Clinic FoundationInventor: Andrei V. Gudkov
-
Patent number: 11235029Abstract: The present invention relates to compositions and methods for the treatment of heart failure.Type: GrantFiled: March 9, 2018Date of Patent: February 1, 2022Assignees: Temple University-Of The Commonwealth System of Higher, Education Johns Hopkins Technology Ventures, Universita di Napoli Federico IIInventors: Alessandro Cannavo, Ning Feng, Giuseppe Rengo, Nazareno Paolocci, Walter J. Koch
-
Patent number: 11235030Abstract: Provided herein are compositions and methods for the treatment of tendinopathies, such as tenosynovitis, tendinosis or tendinitis, including Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis or “tennis elbow,” medial epicondylitis or “golfer's elbow,” plantar fasciitis, and rotator cuff tendinopathy, and in particular to methods for the treatment of tendinopathies by administering compositions comprising platelet-derived growth factor (PDGF).Type: GrantFiled: October 15, 2019Date of Patent: February 1, 2022Assignee: BioMimetic Therapeutics, LLCInventors: Hans K. Kestler, Vivek Shah, Dean James Rager-Aguiar
-
Patent number: 11235031Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.Type: GrantFiled: September 9, 2019Date of Patent: February 1, 2022Assignee: Acorda Therapeutics, Inc.Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
-
Patent number: 11235032Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.Type: GrantFiled: November 22, 2019Date of Patent: February 1, 2022Assignee: Massachusetts Institute of TechnologyInventors: Chensu Wang, Karl Dane Wittrup, Darrell J. Irvine
-
Patent number: 11235033Abstract: The subject invention provides molecules, compositions and methods for treating, preventing or ameliorating vascular calcification, for example, medial vascular calcification or intimal atherosclerotic calcification. The subject invention also provides molecules, compositions and methods for treating or preventing a disease associated with vascular calcification. The methods of the subject invention employ relaxin-based and/or epidermal growth factor receptor (EGFR)-based strategies through the use of RXFP1 agonists and/or EGFR inhibitors.Type: GrantFiled: November 6, 2020Date of Patent: February 1, 2022Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Joshua Hutcheson, Alexander Agoulnik, Hooi Hooi Ng
-
Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism
Patent number: 11235034Abstract: The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.Type: GrantFiled: February 26, 2019Date of Patent: February 1, 2022Assignee: GELITA AGInventors: Steffen Oesser, Stephan Hausmanns, Hans-Ulrich Frech -
Patent number: 11235035Abstract: A method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving dietary phosphorus absorption and retention, or for improving the efficacy of the phytase, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject at least one direct fed microbial in combination with a phytase, wherein the phytase is administered to the subject at a dosage of more than about 1500 FTU/kg feed.Type: GrantFiled: December 4, 2018Date of Patent: February 1, 2022Inventors: Luis Romero, Peter Plumstead, Luke Barnard
-
Patent number: 11235036Abstract: Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human LIPA gene. Some LIPA gene products have been discovered to be associated with reduced lysosomal acid lipase (LAL) activity.Type: GrantFiled: June 16, 2017Date of Patent: February 1, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Andrew Hutchinson, John V. W. Reynders, Guillermo del Angel, Nina Jain, Christen D. Forbes, Xiao-Qin Ren, Barbara Burton
-
Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
Patent number: 11235037Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.Type: GrantFiled: March 14, 2014Date of Patent: February 1, 2022Assignee: Polaris GroupInventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee -
Patent number: 11235038Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: GrantFiled: February 21, 2019Date of Patent: February 1, 2022Assignee: CUREMARK, LLCInventor: Joan M. Fallon
-
Patent number: 11235039Abstract: The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding two or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, and SEQ ID NO: 41.Type: GrantFiled: June 2, 2021Date of Patent: February 1, 2022Assignee: Think Therapeutics, Inc.Inventors: David Gifford, Brandon Carter
-
Patent number: 11235040Abstract: In one embodiment a vaccine composition comprises two or three AChR subunit constructs and an adjuvant. In some embodiments the AChR subunit construct is an AChR ?1 subunit construct, an AChR ?1 subunit construct, an AChR ? subunit construct, an AChR ? subunit construct, or an AChR ? subunit construct. In another embodiment, the invention provides a method of treating myasthenia gravis in a patient in need thereof, comprising administering a vaccine composition comprising one or more acetylcholine receptor subunit constructs selected from the group consisting of AChR ?1 subunit, AChR ?1 subunit, AChR ? subunit, AChR ? subunit, AChR ? subunit, a fragment thereof, and a combination thereof, and an adjuvant.Type: GrantFiled: September 14, 2015Date of Patent: February 1, 2022Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Jon Lindstrom, Jie Luo